MEDA

This article is about the psychedelic drug. For the instrument on the Perseverance rover, see Mars Environmental Dynamics Analyzer.
MEDA
Names
Preferred IUPAC name
1-(8-Methoxy-2,3-dihydro-1,4-benzodioxin-6-yl)propan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
  • InChI=1S/C12H17NO3/c1-8(13)5-9-6-10(14-2)12-11(7-9)15-3-4-16-12/h6-8H,3-5,13H2,1-2H3 ☒N
    Key: NRVFDGZJTPCULU-UHFFFAOYSA-N checkY
  • InChI=1S/C12H17NO3/c1-8(13)5-9-6-10(14-2)12-11(7-9)15-3-4-16-12/h6-8H,3-5,13H2,1-2H3
    Key: HEYPARQBPGSFKW-UHFFFAOYSA-N
  • NC(CC1=CC2=C(OCCO2)C(OC)=C1)C
Properties
C12H17NO3
Molar mass 223.272 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

MEDA (3-methoxy-4,5-ethylenedioxyamphetamine) is a lesser-known psychedelic drug. MEDA was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 200 mg, and the duration unknown.[1] MEDA produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MEDA.

See also

References

  1. ^ MEDA entry in PiHKAL


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.